[
  {
    "ts": "2025-12-22T13:31:39+00:00",
    "headline": "Stock Market Today: Dow Rises As Nvidia Rebounds; AppLovin, Palantir, Tesla Near Buy Points (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rose Monday as Nvidia rebounded in premarket trading. Palantir and Tesla are near buy points.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-nvidia-nvda-applovin-palantir-tesla-stock-tsla/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ea849d8e-7ace-3556-a76d-86cdcfebfe7b",
      "content": {
        "id": "ea849d8e-7ace-3556-a76d-86cdcfebfe7b",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Rises As Nvidia Rebounds; AppLovin, Palantir, Tesla Near Buy Points (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index rose Monday as Nvidia rebounded in premarket trading. Palantir and Tesla are near buy points.",
        "pubDate": "2025-12-22T13:31:39Z",
        "displayTime": "2025-12-22T13:31:39Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ea849d8e-7ace-3556-a76d-86cdcfebfe7b/stock-market-today-dow-rises.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/87c39a949f97ed3e7beb2b2a786c1d3d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hOs1F_TaHb_JZhpg0fpZ4w--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/87c39a949f97ed3e7beb2b2a786c1d3d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vLOLK2750Jx5lj3zrYduvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/87c39a949f97ed3e7beb2b2a786c1d3d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-nvidia-nvda-applovin-palantir-tesla-stock-tsla/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "CAT"
            },
            {
              "symbol": "APP"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "UNH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T08:56:00+00:00",
    "headline": "Radiopharmaceutical specialist Aktis seeks an IPO",
    "summary": "The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.",
    "url": "https://www.biopharmadive.com/news/aktis-oncology-biotech-ipo-radiopharmaceuticals-nectin-4/808472/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "5f67a420-c19c-3e35-9c4b-3d4f060e8a00",
      "content": {
        "id": "5f67a420-c19c-3e35-9c4b-3d4f060e8a00",
        "contentType": "STORY",
        "title": "Radiopharmaceutical specialist Aktis seeks an IPO",
        "description": "",
        "summary": "The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.",
        "pubDate": "2025-12-22T08:56:00Z",
        "displayTime": "2025-12-22T08:56:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xebWKYOkzjDslowFRlBy9Q--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6r2ObCW6Mj9THHRMKUfxsA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7829f4772a4095c81a1f7c9b594ef2e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/aktis-oncology-biotech-ipo-radiopharmaceuticals-nectin-4/808472/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/radiopharmaceutical-specialist-aktis-seeks-ipo-085600017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:27:00+00:00",
    "headline": "Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals",
    "summary": "Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.",
    "url": "https://finance.yahoo.com/news/drug-sector-high-9-drugmakers-132700030.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1a1afba5-b74f-3a1d-b6bd-d7e578a319b9",
      "content": {
        "id": "1a1afba5-b74f-3a1d-b6bd-d7e578a319b9",
        "contentType": "STORY",
        "title": "Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals",
        "description": "",
        "summary": "Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.",
        "pubDate": "2025-12-22T13:27:00Z",
        "displayTime": "2025-12-22T13:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4mGL7zFW4ML.rueGFlAaKQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/i_0DPni3TtRoN19G7I0YLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6e7a581172a57923b1e9381146e28fb5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/drug-sector-high-9-drugmakers-132700030.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/drug-sector-high-9-drugmakers-132700030.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T13:19:00+00:00",
    "headline": "This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.",
    "summary": "Vaxcyte  stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note.  Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants.  It could eventually be a leader in an $8 billion market, Mizuho argued.",
    "url": "https://www.barrons.com/articles/vaxcyte-stock-mizuho-top-pick-36590a36?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "5bed4ebe-57b5-3d93-bd71-9a835377478b",
      "content": {
        "id": "5bed4ebe-57b5-3d93-bd71-9a835377478b",
        "contentType": "STORY",
        "title": "This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.",
        "description": "",
        "summary": "Vaxcyte  stock kept its place as one of Mizuho’s top picks entering 2026, with the firm reiterating an Outperform rating and a $163 price target in a research note.  Vaxcyte is advancing to phase 3 trials for its shot, VAX-31, in adults and phase 2 trials for infants.  It could eventually be a leader in an $8 billion market, Mizuho argued.",
        "pubDate": "2025-12-22T13:19:00Z",
        "displayTime": "2025-12-22T13:19:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/5bed4ebe-57b5-3d93-bd71-9a835377478b/this-pharma-stock-had-a-rough.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/fd096c45abe0a5da604a963bbba9f9fc",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IFRcS6kyRLelHUQgHqge_w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/fd096c45abe0a5da604a963bbba9f9fc.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.gI.fsGAAZAu5.FX.Nea9A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/fd096c45abe0a5da604a963bbba9f9fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/vaxcyte-stock-mizuho-top-pick-36590a36?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PCVX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-22T17:29:37+00:00",
    "headline": "“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer",
    "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early November. Before the run started, the stock was down 16.8% […]",
    "url": "https://finance.yahoo.com/news/merck-mrk-inexpensive-stock-says-172937950.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "13190dd5-50f6-360e-8931-02493ad33b77",
      "content": {
        "id": "13190dd5-50f6-360e-8931-02493ad33b77",
        "contentType": "STORY",
        "title": "“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer",
        "description": "",
        "summary": "We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s radars. Pharma giant Merck & Co., Inc. (NYSE:MRK)’s shares are up by 1.9% year-to-date on the back of a strong run since early November. Before the run started, the stock was down 16.8% […]",
        "pubDate": "2025-12-22T17:29:37Z",
        "displayTime": "2025-12-22T17:29:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tXp3W2zDkWcbYHYM_edP3Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuRra1_S02PEU8kqjSl2RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-inexpensive-stock-says-172937950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-inexpensive-stock-says-172937950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]